Exelixis

Exelixis, Inc. is an oncology-focused biotechnology company headquartered in Alameda, California, dedicated to the discovery, development, and commercialization of innovative treatments for cancer. Founded in 1994, Exelixis has established a robust portfolio of therapies designed to address the unmet medical needs of patients suffering from various forms of difficult-to-treat cancers. With a vision to shape the future of oncology, the company is committed to accelerating the pace of drug discovery and the advancement of clinical development programs.

At Exelixis, cancer is viewed as a pivotal challenge that demands innovative solutions. The company leverages its expertise in biotherapeutics and small molecule discovery to create new treatments that not only aim to enhance the quality of life for patients but also strive for potential cures. Their flagship product, Cabozantinib (CABOMETYX®), has set a precedent for the company’s mission to deliver impactful cancer therapies. Beyond commercial success, Exelixis actively engages in various environmental, social, and governance initiatives to ensure that their mission extends to benefits for the wider community, showing commitment not only to their patients but also to creating a positive societal impact.